Syros Pharmaceuticals (SYRS) Competitors $0.25 +0.04 (+19.71%) (As of 05:46 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SYRS vs. PULM, NNVC, GOVX, MTEX, INKT, ATHA, TENX, AFMD, SNTI, and BFRGShould you be buying Syros Pharmaceuticals stock or one of its competitors? The main competitors of Syros Pharmaceuticals include Pulmatrix (PULM), NanoViricides (NNVC), GeoVax Labs (GOVX), Mannatech (MTEX), MiNK Therapeutics (INKT), Athira Pharma (ATHA), Tenax Therapeutics (TENX), Affimed (AFMD), Senti Biosciences (SNTI), and Bullfrog AI (BFRG). These companies are all part of the "pharmaceutical products" industry. Syros Pharmaceuticals vs. Pulmatrix NanoViricides GeoVax Labs Mannatech MiNK Therapeutics Athira Pharma Tenax Therapeutics Affimed Senti Biosciences Bullfrog AI Pulmatrix (NASDAQ:PULM) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation, community ranking and profitability. Do analysts recommend PULM or SYRS? Syros Pharmaceuticals has a consensus price target of $3.33, indicating a potential upside of 1,232.27%. Given Syros Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Syros Pharmaceuticals is more favorable than Pulmatrix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pulmatrix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Do insiders and institutionals have more ownership in PULM or SYRS? 11.8% of Pulmatrix shares are owned by institutional investors. Comparatively, 91.5% of Syros Pharmaceuticals shares are owned by institutional investors. 0.6% of Pulmatrix shares are owned by company insiders. Comparatively, 12.3% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer PULM or SYRS? In the previous week, Pulmatrix had 1 more articles in the media than Syros Pharmaceuticals. MarketBeat recorded 2 mentions for Pulmatrix and 1 mentions for Syros Pharmaceuticals. Syros Pharmaceuticals' average media sentiment score of 0.25 beat Pulmatrix's score of -0.33 indicating that Syros Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Pulmatrix Neutral Syros Pharmaceuticals Neutral Does the MarketBeat Community believe in PULM or SYRS? Syros Pharmaceuticals received 171 more outperform votes than Pulmatrix when rated by MarketBeat users. Likewise, 62.95% of users gave Syros Pharmaceuticals an outperform vote while only 48.40% of users gave Pulmatrix an outperform vote. CompanyUnderperformOutperformPulmatrixOutperform Votes19648.40% Underperform Votes20951.60% Syros PharmaceuticalsOutperform Votes36762.95% Underperform Votes21637.05% Which has more risk and volatility, PULM or SYRS? Pulmatrix has a beta of 1.54, suggesting that its share price is 54% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Which has preferable valuation and earnings, PULM or SYRS? Pulmatrix has higher revenue and earnings than Syros Pharmaceuticals. Pulmatrix is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPulmatrix$10.01M2.50-$14.12M-$2.64-2.60Syros Pharmaceuticals$386K17.39-$164.57M-$3.03-0.08 Is PULM or SYRS more profitable? Syros Pharmaceuticals has a net margin of 0.00% compared to Pulmatrix's net margin of -96.51%. Pulmatrix's return on equity of -45.97% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Pulmatrix-96.51% -45.97% -30.72% Syros Pharmaceuticals N/A -3,369.56%-97.04% SummarySyros Pharmaceuticals beats Pulmatrix on 11 of the 18 factors compared between the two stocks. Ad StocksToTradeTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’s promise, and a secret Elon project set to revolutionize a $23 Trillion market…Click here to review Tim’s special Holiday offer before it’s too late. Get Syros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SYRS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYRS vs. The Competition Export to ExcelMetricSyros PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.71M$6.58B$5.16B$9.02BDividend YieldN/A2.96%4.96%4.19%P/E Ratio-0.0810.6086.4717.05Price / Sales17.39195.851,126.05116.49Price / CashN/A57.1543.2737.84Price / Book0.325.124.824.96Net Income-$164.57M$150.98M$120.07M$225.17M7 Day Performance22.71%1.72%1.23%4.45%1 Month Performance-7.85%-5.99%16.54%3.07%1 Year Performance-96.79%6.01%28.85%17.61% Syros Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYRSSyros Pharmaceuticals4.3905 of 5 stars$0.25+19.7%$3.33+1,232.3%-97.3%$6.71M$386,000.00-0.08120Short Interest ↓High Trading VolumePULMPulmatrix0.1231 of 5 stars$5.84-2.7%N/A+244.1%$21.33M$10.01M-2.2120Analyst ForecastShort Interest ↑Gap DownNNVCNanoViricidesN/A$1.51+1.3%N/A+45.6%$21.06MN/A-1.9920Gap UpHigh Trading VolumeGOVXGeoVax Labs1.8809 of 5 stars$2.23-2.6%$14.20+536.8%-54.6%$21.04M$3.09M0.0017Short Interest ↑MTEXMannatech0.5431 of 5 stars$10.88-8.3%N/A+35.8%$20.51M$121.55M-13.43250Analyst ForecastNews CoverageGap UpINKTMiNK Therapeutics1.9343 of 5 stars$0.52-1.2%$6.50+1,156.0%-46.3%$20.47MN/A-1.3330Short Interest ↑Negative NewsGap UpATHAAthira Pharma3.4312 of 5 stars$0.51-11.0%$13.83+2,598.1%-77.4%$19.83MN/A-0.1840Short Interest ↓Positive NewsTENXTenax Therapeutics1.4976 of 5 stars$5.60-0.2%$16.00+185.7%-71.3%$19.09MN/A0.009Short Interest ↑News CoverageNegative NewsGap UpAFMDAffimed4.2147 of 5 stars$1.17-1.6%$13.50+1,052.8%-79.4%$18.86M$877,000.000.0076Short Interest ↑Positive NewsGap UpSNTISenti Biosciences2.7823 of 5 stars$4.05+2.0%$10.00+146.9%-40.6%$18.59M$2.56M-0.264Short Interest ↑Gap DownBFRGBullfrog AI1.3728 of 5 stars$2.09flatN/A-32.2%$18.21M$60,000.00-2.464News Coverage Related Companies and Tools Related Companies PULM Alternatives NNVC Alternatives GOVX Alternatives MTEX Alternatives INKT Alternatives ATHA Alternatives TENX Alternatives AFMD Alternatives SNTI Alternatives BFRG Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SYRS) was last updated on 12/30/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuy this Stock before Trump Takes Office!To make sure everyone has the opportunity to get in, closes for good at midnight on January 1st, we're lowerin...Behind the Markets | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
